Evidence map›Paper›PMID 32978608›Full record

ReviewNature reviews. Clinical oncology2021

CAR T cell therapies for patients with multiple myeloma.

Lekha Mikkilineni, James N Kochenderfer

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04662099 (Safety and Efficacy of the Bispecific CAR T Therapy Targeting CS1 and BCMA in Patients With Relapsed/ Refractory Multiple Myeloma), which is not on this map. Cited by 146 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
146citing papers in PubMed, 5 pooled it
13.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04662099 phase1unknown statusnot on this map

Safety and Efficacy of the Bispecific CAR T Therapy Targeting CS1 and BCMA in Patients With Relapsed/ Refractory Multiple Myeloma: a Single-center, Open-label, Single-arm Clinical Study

TypeinterventionalSponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyRan2020 to 2023Enrolled24ConditionsCS1+ or BCMA+ Multiple MyelomaArmsConditioning chemotherapy followed by CAR T cell infusion
3 · Its place in the literature

Who cites it

146 citing papers in PubMed, 5 syntheses or guidelines pooled it, 266 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Review
  9. Review
  10. Review
  11. DNA-directed assembly of multivalent lipid nanoparticles for targeted T cell gene delivery.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Saga of MCL1 inhibitors in multiple myeloma.Biochemical pharmacology · 2026
    Review
  19. Article
  20. Review

86 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Lekha MikkilineniSurgery Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA. lekha.mikkilineni@mail.nih.gov.
James N KochenderferSurgery Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-4362-9875
Center for Cancer Research · US

Funding

Development of Chimeric Antigen Receptors Targeting Multiple MyelomaZIABC011439 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KOCHENDERFER, JAMES · 2012 to 2025
$9.5M
6 · The paper itself

Abstract

Despite several therapeutic advances over the past decade, multiple myeloma (MM) remains largely incurable, indicating a need for new treatment approaches. Chimeric antigen receptor (CAR) T cell therapy works by mechanisms distinct from those of other MM therapies and involves the modification of patient or donor T cells to target specific cell-surface antigens. B cell maturation antigen (BCMA) is expressed only on plasma cells, a small subset of B cells and MM cells, which makes it a suitable target antigen for such therapies. At the time of writing, data from >20 clinical trials involving anti-BCMA CAR T cells have demonstrated that patients with relapsed and/or refractory MM can achieve objective responses. These early investigations have been instrumental in demonstrating short-term safety and efficacy; however, most patients do not have disease remission lasting >18 months. Attempts to reduce or delay the onset of relapsed disease are underway and include identifying additional CAR T cell target antigens and methods of enhancing BCMA expression on MM cells. Engineering CAR T cells to enhance both the activity and safety of treatment continues to be a promising avenue for improvement. In this Review we summarize data from clinical trials that have been carried out to date, describe novel antigens that could be targeted in the future, and highlight potential future innovations that could enhance the efficacy and/or reduce the toxicities associated with CAR T cell therapies.

Indexed as

Amyloid Precursor Protein SecretasesB-Cell Maturation AntigenClinical Trials as TopicHumansImmunotherapy, AdoptiveMolecular Targeted TherapyMultiple MyelomaNeoplastic Stem CellsReceptors, Antigen, T-CellReceptors, Chimeric AntigenAmyloid Precursor Protein SecretasesB-Cell Maturation Antigenidecabtagene vicleucelReceptors, Antigen, T-CellReceptors, Chimeric AntigenTNFRSF17 protein, human

Identifiers

PMID32978608
OpenAlexW3089287956

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.